ComplyRx

Neuroscience · Live ClinicalTrials.gov data

Donanemab (Kisunla) clinical trial pipeline

ClinicalTrials.gov lists 15 phase 2–4 trials for donanemab (Kisunla), 4 of them actively recruiting. The next phase 3 primary completion among them is expected Nov 2027. Refreshed daily. Add up to four competitors to compare pipelines side by side.

15

Phase 2–4 trials

7

Phase 3 trials

4

Actively recruiting

Nov 2027

Next phase 3 primary completion

10,642

Participants across trials

Eli Lilly and Company

Lead sponsor by trial count

donanemab (15)12 active2017–2032
donanemab
Key
Actual date
Anticipated
Forecast to primary completion
RecruitingActive, not recruitingEnrolling by invitationNot yet recruitingCompleted
'17
'19
'21
'23
'25
'27
'29
'31
donanemab
A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)P2
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)P3
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)P2
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)P3
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)P3
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)P3
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)P3
A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's DiseaseP2
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's DiseaseP3
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)P2
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).P3
ATPP2
ALADDINP4
REVITAA-ALZP2
ATPP2

Upcoming readouts

10 ahead · donanemab

Select a trial to load its full ClinicalTrials.gov record.

Key donanemab trials

Top 12 of the 15 registered phase 2–4 trials, ordered by phase and status. Trial names open the full ComplyRx trial page; NCT ids link to ClinicalTrials.gov.

TrialTitlePhaseStatusPrimary completion
NCT06911944ALADDIN: Amyloid Lowering for Alzheimer's in Down's With Donanemab InvestigationPhase 4Not yet recruitingDec 2028
NCT07602582A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT…Phase 3RecruitingSept 2029
NCT07571161Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Al…Phase 3RecruitingApr 2030
NCT04437511A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ…Phase 3Active, not recruitingApr 2023
NCT05738486A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Dise…Phase 3Active, not recruitingMay 2024
NCT05026866A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-…Phase 3Active, not recruitingNov 2027
NCT05508789A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRA…Phase 3Active, not recruitingMay 2028
NCT05108922A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic…Phase 3CompletedSept 2022
NCT07589595A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7…Phase 2RecruitingAug 2028
NCT06957418ATP: Alzheimer's Tau Platform: Master ProtocolPhase 2RecruitingAug 2028
NCT07756294REVITAA-ALZ: Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's DiseasePhase 2Not yet recruitingApr 2028
NCT07167966ATP: Alzheimer's Tau Platform: Regimen A - AADvac1Phase 2Enrolling by invitationAug 2028

Track donanemab with ComplyRx

Get an alert when a trial changes status, moves its completion date, or a new trial registers in scope. Checked nightly against ClinicalTrials.gov.

Track donanemab

Related drug pipelines

Compare donanemab vs lecanemabCompare donanemab vs xanomeline-trospium

FAQ

How many clinical trials are running for donanemab?
ClinicalTrials.gov currently lists 15 phase 2–4 donanemab trials: 7 phase 2, 7 phase 3, and 1 phase 4. 4 are actively recruiting.
Are there clinical trials for Kisunla?
Kisunla is the brand name for donanemab, so donanemab trials on ClinicalTrials.gov cover it. ClinicalTrials.gov currently lists 15 phase 2–4 donanemab trials: 7 phase 2, 7 phase 3, and 1 phase 4. 4 are actively recruiting.
Where does this data come from?
All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
Can I compare donanemab against other drugs?
Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.
Join the waitlist

Be the first to access ComplyRx

We'll let you know as soon as your spot opens to use ComplyRx.

By joining, you agree to our Privacy Policy.